Sugemalimab Versus Placebo, in Combination with Platinum-Based Chemotherapy, As First-Line Treatment of Metastatic Non-Small-cell Lung Cancer (GEMSTONE-302): 4-Year Outcomes from a Double-Blind, Randomised, Phase 3 Trial.
The Lancet Oncology(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined